Mylan Pharmaceuticals has unveiled Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150mg, a generic version of Mayne Pharma's Doryx 150mg product.
The company begins the shipment of the product.
Mayne Pharma's Doryx 150mg product is marketed by Warner Chilcott and is a tetracycline-class antimicrobial.
The launch follows the favorable US District Court decision in a patent infringement lawsuit brought by Warner Chilcott.
The court ruled that Mylan's product does not infringe the subject patent.
For the 12 months ending 31 December 2011, Doxycycline Hyclate DR Tablets, 150 mg, had US sales of approximately $264.1m, according to IMS Health.
Source:
http://drugdiscovery.pharmaceutical-business-review.com/news/mylan-unveils-generic-doryx-tablets-010512